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Research in context 
Evidence before this study 
Ovid databases (MEDLINE, Embase, PsychINFO) were searched for articles relating to 
health-related quality of life (HRQL) and “localised”, “advanced”, “metastatic”, “stage” and 
“prostate cancer” or “prostatic neoplasms” from June 1996 to June 2018.  Studies were 
excluded if they had no measure of health-related quality of life and were included if they 
included men with either early, late or combined stage prostate cancer.  Most articles relate to 
men with localised disease, with good quality evidence collected in the setting of clinical trials 
and observational studies of specific cohorts.  Few studies have focused on those diagnosed 
with locally advanced or metastatic prostate cancer (PCa).  In the small number of studies 
separating results by stage, poorer HRQL has been associated with later stage of disease.  
However, sample sizes tend to be small.  Therefore, little is known about the impacts of PCa 
in men living with and beyond a diagnosis of advanced disease, especially in comparison to 
men with non-metastatic disease. 
Added value of the study 
To our knowledge, this is first study able to compare, at scale, the HRQL and functional 
outcomes of men living with localised and advanced PCa.  Data were collected on 35,823 
men, with diagnostic stage available on 30,733 of whom 23.4% had stage III disease and 
12.8% stage IV.  The population-based approach enables true definition of the quality of 
survival of the increasingly prevalent group of men living with and beyond PCa.  We identified 
that men with stage III and IV disease reported more problems, including those generic to 
health and those related to treatment, particularly androgen deprivation therapy (ADT).  Poor 
sexual function was reported by most men, regardless of stage, and the majority (55.8%) 
reported not being offered any intervention or support for this.  Despite specific functional 
morbidities, many men with PCa self-reported their overall health to be similar to men in 
general population studies and a substantial proportion of men with stage IV disease (23.5%) 
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reported no problems on any EQ-5D dimension.  These results highlight areas of unmet need 
and will be vital in helping men make informed decisions about their treatment. 
Implications of all the available evidence 
Most men living 18-42 months after a diagnosis of PCa can expect to experience as good 
HRQL as men in the general population, including those with stage III and a substantial 
proportion of those with stage IV disease.  Although sexual morbidity is common, the majority 
of men are not offered helpful intervention or support.  The evidence suggests that there are 
subgroups of men who would benefit from service improvements around sexual rehabilitation 
and measures to minimise the use of ADT.  These include wider use of intermittent ADT 
(versus continuous use), the avoidance of unnecessary ADT (i.e. for non-metastatic disease) 
and the use of shorter neoadjuvant courses (reduced from 3 years to 1 year).  This study 
collected data from men living up to a maximum of 42 months beyond diagnosis.  Those with 
stage IV disease are likely to experience deterioration in their HRQL at some point following 
this.  Further evidence is needed to inform appropriate service provision for them in these later 
years. 
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Abstract 
 
Background: Little is known about the health-related quality of life (HRQL) of men living with 
advanced prostate cancer.  We report population-wide functional outcomes and HRQL in men 
with all stages of prostate cancer, and identify implications for healthcare delivery. 
Methods: Men alive 18-42 months after diagnosis of prostate cancer were identified through 
cancer registration data.  A postal survey was administered which contained validated 
measures to assess a) functional outcomes (EPIC-26 plus use of interventions for sexual 
dysfunction) and b) generic HRQL (EQ-5D-5L & self-assessed health). Log-linear and binary 
logistic regression models were used to compare functional outcomes and HRQL across 
diagnostic stage and self-reported treatment groups. 
Findings: 35,823 (60.8%) men responded.  Stage was known for 85.8%; 19,599 (63.8%) 
stage I/II, 7,209 (23.4%) stage III, 3,925 (12.8%) stage IV.   Functional outcomes: Poor sexual 
function was common (81.0%), regardless of stage, and over half of men (55.8%) received no 
intervention for this.  Differences in urinary and bowel morbidity were greater with respect to 
treatment than stage.  In men treated with androgen deprivation therapy (ADT), 30.7% 
reported moderate/big problems with hot flushes, 29.4% with lack of energy and 22.5% with 
weight gain.  HRQL: Overall self-assessed health was similar in men with stage I-III disease, 
and whilst reduced in those with stage IV cancer, 23.5% with metastatic disease reported no 
problems on any EQ-5D dimension.   
Interpretation: Men diagnosed with advanced disease do not report markedly different HRQL 
outcomes to those diagnosed with localised disease, although substantial problems with 
hormonal function and fatigue are reported amongst men treated with ADT.  Sexual 
dysfunction is common and the majority of men are not offered helpful intervention or support.  
Service improvements around sexual rehabilitation and measures to reduce the impact of ADT 
are required.   
Funding: The Movember Foundation, in partnership with Prostate Cancer UK.  
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Background  
The number of prostate cancer (PCa) survivors has increased rapidly over recent decades.  
According to population-based cancer registry data, 10-year survival has tripled in the last 40 
years in the United Kingdom (UK)1.  In England, there are an estimated 325,000 men alive 
having been diagnosed with PCa between 1995 and 20152.  A principal challenge for 
healthcare is to understand the needs of this growing group of men, in particular the problems 
and challenges faced by those living with advanced disease (30% of men with distant 
metastases now survive at least five years3).  The quality of survival experienced, with 
definition of the specific impacts of the disease and its treatment, must be robustly determined 
to facilitate appropriate care provision4.  
Significant sexual, urinary and bowel morbidities have been identified following treatment of 
localised PCa, with the pattern and severity of morbidity varying according to the type and 
intensity of treatment received5-8.  Most intelligence originates from randomised controlled 
trials and observational studies of specific cohorts, often reporting outcomes following surgery 
compared to radiotherapy and surveillance in men with localised PCa9.  Evidence for the UK 
has not been generated at an unselected population level.  In addition, few studies have 
reported outcomes in men with locally advanced or metastatic disease.  Such studies tend to 
be small and are mostly clinical trials comparing specific treatment types10-12.   
The Life After Prostate Cancer Diagnosis (LAPCD) study adopts an established approach to 
the measurement of population-level health-related quality of life (HRQL), previously used in 
a national population of colorectal cancer survivors13, and extends this to men living with all 
stages of PCa 18-42 months post diagnosis.  This timeframe was chosen as it represents the 
period when initial treatment is complete and side effects/HRQL have begun to stabilise5.  In 
men with advanced disease, treatment with androgen deprivation therapy (ADT) starts at 
diagnosis and therefore any ADT-related effects would be captured.  An internationally 
recommended series of outcome measures has been utilised to facilitate comparison and 
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interpretation, with specific enquiry as to the impact of interventions offered for sexual 
dysfunction14.   
Here we quantify and compare a) functional outcomes (urinary, bowel, sexual and 
vitality/hormonal) and b) HRQL of men with PCa across all disease stages and treatment 
groups, and identify implications for healthcare delivery. 
Methods 
The LAPCD methodology has been reported in full15 but is outlined below. 
Study design and participants 
All National Health Service (NHS) Hospital Trusts/Health Boards treating PCa in the UK were 
approached.  In England, 111 of 136 Trusts participated; 21 declined and 4 were involved in 
overlapping studies.  All Trusts/Health Boards in Northern Ireland (NI; n=5), Scotland (n=14) 
and Wales (n=6) participated.  Men alive 18-42 months after a PCa diagnosis (ICD1016 C61) 
in participating Trusts/Boards were identified from national population-based cancer registries 
in England, NI and Wales.  In Scotland, due to privacy restrictions, men were identified through 
hospital activity data and verified through the cancer registry.  There was no age limit for 
inclusion. Approximately 82% of eligible men with PCa across the UK were invited to 
participate.     
The study received the following approvals: Newcastle & North Tyneside 1 Research Ethics 
Committee (15/NE/0036), Confidentiality Advisory Group (15/CAG/0110), NHS Scotland 
Public Benefit and Privacy Panel (0516-0364) and NHS R&D approval from Wales, Scotland 
and Northern Ireland.  These approvals allowed men to be contacted using details held within 
cancer registration/hospital activity data.  The study protocol can be found at 
https://bmjopen.bmj.com/content/6/12/e013555. 
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Procedures 
Men were sent a postal survey (Appendix p2-22) on behalf of their treating Trust/Board.  Men 
consented by returning completed surveys and declined by not returning them, returning them 
unanswered or opting out via a free-phone helpline.  Up to two reminders were sent to non-
responders.  The data collection period differed by nation: England 16/10/2015-21/04/2016; 
NI 14/06/2016-18/10/2016; Scotland 20/07/2016-01/11/2016; Wales 28/07/2016-09/11/2016).  
The survey included a range of validated measures, including those defined in the 
International Consortium on Health Outcome Measurement (ICHOM) minimum outcome 
dataset14: the Expanded Prostate cancer Index Composite short form (EPIC-26)17; items on 
use of interventions to improve sexual function; and EQ-5D-5L18.  The survey additionally 
included questions relating to socio-demographics and treatments received. 
Stage at diagnosis was obtained from national cancer registration records.  Stage I and II were 
combined into a ‘localised disease’ group and compared to stage III and IV separately.  An 
area-based measure of socio-economic deprivation (split into quintiles) was derived using 
postcode of residence19-22.  Age, presence of other long-term conditions and treatments 
received were derived from the survey response data.  Age was categorised as <55, 55-64, 
65-74, 75-84, and ≥85 years.  Where missing, this was supplemented by cancer registration 
data (accounting for the lag between diagnosis and survey).  Other long-term conditions 
(Appendix, p19 question 84) were counted and categorised as none, 1, 2, 3, ≥4.  Treatments 
(Appendix, p5-6 question 8) were categorised into single therapies (e.g. surgery alone or 
external beam radiotherapy [EBRT] alone) or combinations therapies (e.g. EBRT and ADT) 
(Appendix p23).   
A User Advisory Group, including 6 PCa survivors, was chaired by HB (co-investigator and 
PCa survivor).  The group has been involved in all stages of the study from design through to 
interpretation and dissemination of results.  
Outcomes 
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Functional outcomes: EPIC-26 measures function across five domains (urinary incontinence, 
urinary irritation and obstruction, bowel, sexual, vitality/hormone), using 26 items.  Domain 
scores range from 0-100, with 100 representing best possible function.  Mean domain scores 
were calculated.  Where one item in a domain was missing, this was substituted with the mean 
of the available items, as per the scoring guidance23.  In addition to mean scores, individual 
item responses were used to derive the proportion reporting a moderate/big problem (or 
equivalent), as per Watson et al24. 
The ICHOM dataset includes two items assessing use of medications and devices for erectile 
dysfunction25.  These were amended to avoid drug/trade names (Appendix, p12 questions 25-
26).  An extra item on use of specialist services to help with sex life was included (Appendix, 
p13 question 27).  The possible response categories were grouped as ‘not offered’, ‘offered 
but did not want/try it’, ‘offered but did not help’, ‘offered and it helped’.  
HRQL: EQ-5D-5L records information on five dimensions (mobility, self-care, usual activities, 
pain/discomfort, anxiety/depression), plus a rating of self-assessed health (SAH) based on 
“how good or bad your health is today” (valued 0-100, where 100 represents best possible 
health).  The proportion of respondents reporting any problem, regardless of severity, in each 
dimension separately and across all five dimensions was derived.  Mean SAH ratings were 
calculated. 
Statistical analysis 
All men who completed questionnaires were included in analyses.  However, as not all men 
completed every item, records with missing responses were excluded on a question-by-
question basis, thus results refer to the men who responded to that question.  Log-linear 
regression was used to model the continuous outcomes (mean EPIC-26 domain scores and 
mean EQ-5D SAH score), as this approach provided a better fit to the data than a linear one.  
Binary logistic regression models were developed for each individual EPIC-26 item (with 
moderate/big problems, or equivalent, as the outcome) and each EQ-5D dimension (with 
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reporting of any problem as the outcome).  For each outcome, results were generated by 
disease stage and treatment group, by adding these variables separately to the models.  Each 
model included adjustment for age (as a linear term), socio-economic deprivation and number 
of other long-term conditions.  Subgroup analyses by age group were adjusted for socio-
economic deprivation and other long-term conditions.  Resulting model coefficients were used 
to predict the mean scores (for the EPIC-26 domains and SAH) and proportions reporting 
problems (for the individual EPIC-26 items and EQ-5D dimensions) along with 95% confidence 
intervals for each stage and treatment group, taking account of the different case-mix profiles 
of each group.  Analysis of the use of interventions for sexual dysfunction was based on the 
raw survey responses, in order to reflect ‘real world’ provision of sexual support to men with 
prostate cancer.   Due to the large number of men included in the study, statistical significance 
can be achieved with only small differences in outcomes, and these may not be clinically 
relevant.  As such, to aid interpretation, results are presented alongside previously estimated 
minimally important differences (MIDs), where available26-28.  Analyses were performed using 
Stata version 15.0 (StataCorp, TX, USA).  
Role of the funding source 
The funders of the LAPCD study had no role in the design of the study, the data collection, 
analysis and interpretation, the writing of the manuscript or the decision to submit for 
publication.  Anonymised study data were available to AD and SW. The corresponding author 
had full access to the anonymised data and had final responsibility to submit the article for 
publication.   
Results 
A total of 59,990 eligible men were identified; 1,060 (1.8%) died during the study period, giving 
a final sample of 58,930.  Of these, 35,823 returned completed questionnaires (60.8% 
response) (Appendix p28).  Men aged under 55 (51.8% response) or over 85 (36.9% 
response), from non-white ethnic groups (38.0% response) and those living in the most socio-
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economically deprived areas (48.3% response) were less likely to participate (Appendix p24).  
By stage, response rates were highest in the men diagnosed with stage III cancer (65.7%) 
and lowest in those diagnosed with stage IV disease (58.1%). Within the completed 
questionnaires, levels of missing data were generally low e.g. <3% missing for EQ-5D 
(Appendix p25).  EPIC-26 items were less well completed and domain scores could not be 
calculated in 9-18% of cases.  Completion was highest for the sexual function domain and 
lowest for the urinary irritation domain.  
Of the 35,823 men who completed questionnaires, 16,638 (46.4%) were aged 65-74 at survey 
(median 71 years, IQR 67-77) (Table 1).  A quarter (9,408; 26.3%) of the men lived in the least 
socio-economically deprived areas and 3,620 (10.1%) lived in the most deprived areas.  Most 
men (25,418; 71.0%) reported at least one other long-term condition, with 2,563 (7.2%) 
reporting four or more.   
Stage at diagnosis was known for 30,733 (85.8%) of respondents, of whom 19,599 (63.8%) 
had stage I or II disease, 7,209 (23.4%) stage III, and 3,925 (12.8%) stage IV.  Table 1 details 
the characteristics of each stage group, including those with unknown stage.  The men 
diagnosed with stage IV disease (median age 73 years, IQR 68-79) were older than those 
with stage I/II disease (median age 71 years, IQR 66-76).  The median age of the group with 
unknown stage was 73 (IQR 67-79).  The socio-economic deprivation and long-term condition 
profiles were similar across the known stage groups, whilst a higher proportion of the group 
with unknown stage lived in the least socio-economically deprived areas (p<0.001).    
The treatments reported by the men are detailed in Table 1. Across the whole cohort, 7,488 
(20.9%) reported receiving combined EBRT and ADT, with a further 7,054 (19.7%) reporting 
having surgery alone (Table 1).  Of those diagnosed with stage I/II disease, 3,986 (20.3%) 
reported being on a monitoring regime (active surveillance (AS) or watchful waiting) and 4,606 
(23.5%) reported having surgery alone.  Most men diagnosed with stage IV cancer were 
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receiving ADT at the time of survey, either alone (1,116; 28.4%) or in combination with EBRT 
and/or other systemic therapy (chemotherapy, Abiraterone, Enzalutamide) (1,597; 40.7%).   
Mean adjusted EPIC-26 domain scores were high, indicating good function, except for sexual 
function where scores were much lower (24.0, 95% CI 23.6-24.2) (Table 2).  Urinary and bowel 
function were similar across all disease stages (<3 point difference), whereas vitality/hormone 
and sexual function were substantially reduced in men with stage III and IV PCa compared to 
those with localised disease (8-16 point difference for hormone function and 12-17 point 
difference for sexual function).  Men treated surgically reported more urinary incontinence, 
whilst those on ADT reported worse hormonal and sexual function.     
Needing to urinate frequently was the most common urinary symptom (adjusted proportion: 
18.6%, 95% CI 18.1-19.0 reported a moderate/big problem), followed by leaking at least once 
per day (adjusted proportion: 12.7%, 95% CI 12.3-13.0).  There were only small differences 
in the reporting of urinary symptoms by stage (Figure 1a).  Men who underwent surgery 
reported high levels of urinary incontinence (23.4%, 95% CI 22.3-24.5 leaked at least once 
per day and 31.4%, 95% CI 30.2-32.6 used one or more pads per day in the surgery alone 
group) (adjusted proportions: Appendix p26).  Problems with urinary frequency and weak 
stream/incomplete emptying were less of a problem in the ‘surgery alone’ group than in other 
treatment groups.    
Problems with bowel function were relatively infrequent compared to other domains and varied 
little by stage of disease (Figure 1a).  Bowel urgency was the most common bowel problem 
(adjusted proportion: 8.8%, 95% CI 8.5-9.2 reported a moderate/big problem).  Bowel 
problems were more frequent following EBRT, alone or in combination.  For example, 11.4% 
(95% CI 10.2-12.7) of the ‘EBRT alone’ group reported moderate/big problems with bowel 
urgency compared to 4.4% (95% CI 3.9-4.9) in the ‘surgery alone’ group (adjusted proportions: 
Appendix p26). 
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With respect to vitality/hormone function, problems with lack of energy, hot flushes and weight 
gain were most commonly reported.  There were much larger differences in the reporting of 
these symptoms by stage than was seen for urinary and bowel function (Figure 1a), however, 
this is related to the treatment received.  Men treated with ADT, alone or in combination with 
other therapy, reported much higher rates of problems with hormonal function and fatigue.  
For example, 30.7% (95% CI 29.8-31.6) of men treated with ADT reported moderate/big 
problems with hot flushes (compared to 5.4%, 95% CI 5.0-5.8 in the no-ADT group) and 29.4% 
(95% CI 28.6-30.3) of men treated with ADT reported problems with lack of energy (compared 
to 14.7%, 95% CI 14.2-15.3 in the no-ADT group) (adjusted proportions: Figure 1b).  There 
was a smaller difference in the reporting of depression between the ADT and no-ADT groups 
(11.4%, 95% CI 10.8-12.0 and 6.6%, 95% CI 6.2-7.0 reporting moderate/big problems). 
Problems with sexual function were more common than issues in other domains: poor/very 
poor erections (81.5%, 95% CI 81.1-82.0), poor/very poor ability to reach orgasm (76.6%, 95% 
CI 76.1-77.1) and poor/very poor overall sexual function (81.0%, 95% CI 80.6-81.5).  In men 
with localised disease, 75.0% (95% CI 74.3-75.6) reported poor/very poor sexual function, as 
did 90.4% (95% CI 89.7-91.1) of men with stage III and 96.0% (95% CI 95.3-96.6) of men with 
stage IV cancer (adjusted proportions: Figure 2a).  By treatment, just over half of men on AS 
(51.1%, 95% CI 49.1-53.1) reported poor/very poor overall sexual function, increasing to 
83.7% (95% CI 82.8-84.6) of men who had surgery alone and 93.6% (95% CI 92.4-94.7) 
receiving ADT alone (adjusted proportions: Appendix p26).  By age, just over half (54.5%, 
95% CI 50.7-58.4) of the men aged <55 reported poor/very poor sexual function and this 
increased sharply with age (Figure 2b).  A substantial proportion of men (all age groups: 
45.2%, 95% CI 44.7-45.8) perceived their (lack of) sexual function to be a moderate/big 
problem; however, this decreased slightly with age.    
Across the cohort, 13,972 men (41.4%) reported being offered medications to aid or improve 
erections, 7,621 (22.6%) were offered devices to aid erections and 4,894 (14.8%) were offered 
specialist services to help with sex life (Appendix p27).  Over half (18,871; 55.8%) were not 
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offered any of these interventions.  More of the younger men reported having been offered 
intervention: however, even in the youngest age group (<55 years), 153 men (23.5%) were 
not offered medications, 320 (48.9%) were not offered devices and 493 (76.0%) were not 
offered access to specialist services (Figure 3).  By stage, similar proportions of men with 
stage I/II (8,678; 46.7%) and stage III (3,247; 47.7%) disease were offered any of the 
interventions compared to 957 (26.9%) with stage IV.  The proportion of men being offered 
intervention varied greatly according to the type of treatment received.  For example, 5,567 
(80.9%) of men having surgery alone, 735 (62.9%) of men having brachytherapy alone, 812 
(34.5%) of men having EBRT alone and 523 (18.8%) of men having ADT alone were offered 
one of the three interventions.  
Amongst men offered any of the three interventions, 5,534 (37.2%) did not want them or did 
not try them, 3,546 (23.8%) found they did not help, and 5,812 (39.0%) reported at least one 
of them being helpful (Appendix p27).  Of those offered medications, 4,474 (34.2%) reported 
them being helpful.  Of those offered devices, 2,154 (28.3%) reported them as helpful.  For 
those offered specialist services, 943 (18.9%) found them helpful.   
The overall mean adjusted SAH score was 76.3 (95% CI 76.1-76.5) (Table 2).  SAH was 5.7 
points lower in men with stage IV disease compared to men with localised cancer (mean 
adjusted scores: 71.7 (95% CI 71.1-72.3) and 77.4 (95% CI 77.2-77.7) respectively).  Men 
with stage III disease reported a mean adjusted SAH score of 76.3 (95% CI 75.9-76.7).  When 
looking across the age groups, the difference in SAH between stage I/II and stage IV was 
greater in the younger men (Figure 4a). A similar pattern was seen when looking at the effect 
of ADT use by age (Figure 4b).  
Looking at the EQ-5D dimensions, men reported the most problems (of any level) with 
‘pain/discomfort’ (41.7%, 95% CI 41.1-42.2) and fewest problems with ‘self-care’ (11.5%, 95% 
CI 11.1-11.9) (adjusted proportions: Table 2).  Men with stage IV cancer reported more 
problems in each dimension, and this was highest for ‘pain/discomfort’ (54.6%, 95% CI 53.0-
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56.3) and ‘usual activities’ (53.3%, 95% CI 51.6-55.0).  Of those with stage IV PCa, 76.5%, 
(95%CI 75.2-77.9) reported ≥1 problem on EQ-5D , compared to 59.8% (95% CI 59.1-60.1) 
of stage I/II and 64.7% (95% CI 63.6-65.9) of stage III men.   Nearly a quarter of men with 
stage IV disease reported no problems on any EQ-5D dimension. 
Discussion  
To our knowledge, this is the largest population-based patient-reported outcomes study of 
men with PCa to date.  It includes 11,000 men living with locally advanced or metastatic 
disease, an increasingly prevalent cohort of cancer survivors, frequently excluded from study.  
The majority of those with stage III disease and approximately 25% with stage IV disease 
report good overall HRQL.  However, sexual morbidity is high, irrespective of stage of disease, 
with over half of men reporting they had not been offered intervention to help with this.  More 
than other treatments, men treated with ADT reported poorer outcomes.   
Approaching 80% of the cohort reported poor or very poor sexual function and this was 
consistently high across the disease stages.  A recent study of older men in the general 
population found that 48% reported poor sexual function29.  In this study, 51% of men on active 
surveillance reported poor sexual function, which is unlikely to be related to the diagnosis of 
PCa as they have not received any active treatment.  Hence, whilst sexual dysfunction is 
common in the general population, the levels reported by men treated for PCa are 
considerably higher.  Sexual dysfunction increased with age and is likely partly explained by 
the normal ageing process.  However, the data show that older men are less ‘bothered’ by 
their lack of sexual function.  In the youngest men, around 50% reported poor function and the 
same proportion reported it to be a problem.  In the older men, over 80% reported poor function 
but they were less likely to be ‘bothered’ by it.  Overall, 56% reported not being offered access 
to medications, devices or specialist services to improve sexual function, and only 40% of 
those offered help found it to be beneficial.  Access to these interventions varied by age and 
by treatment received.  Further analysis of these data is needed to look at this variation in 
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more detail and to understand which groups of men are finding the interventions helpful.  
However, to our knowledge, this extent of failure to receive support has not previously been 
described.  This intelligence would suggest clinical services need to proactively address this 
and ensure that sexual support is routinely offered to all men.  However, it must be 
acknowledged that not all men see their lack of sexual function as a problem and some will 
not want intervention to address this.   
Overall levels of urinary and bowel problems in men with PCa are relatively low; however, 
there are subgroups with increased levels of dysfunction.  For example, men treated surgically 
reported higher levels of urinary incontinence with 30% reporting using pads daily, a finding 
which supports previous research5,8.  These men are between 18 and 42 months post-
diagnosis and there may be some recovery in function with longer follow-up5.   
In general, those with stage III and IV disease reported a higher level of problems, but in many 
cases these differences were small and were less than previously estimated MIDs for urinary 
and bowel function28.  Larger impacts on sexual function, hormonal function, fatigue and 
depression were seen and will, in part, be driven by treatment with ADT.  The majority of men 
with stage III or IV PCa will be on long-term or indefinite ADT.  There may be some recovery 
in those who stop ADT, with a corresponding reduction in symptoms, but testosterone levels 
may never recover to pre-treatment levels.  Longer-term follow-up of men would be required 
to assess recovery of sexual function, levels of fatigue and other ADT-related effects.  The 
results suggest that clinicians should pursue treatment approaches that preserve testosterone 
function when possible and minimise ADT use.  Steps to reduce ADT-related morbidity might 
include wider use of intermittent ADT (versus continuous use), the avoidance of unnecessary 
ADT (i.e. for non-metastatic disease) and the use of shorter neoadjuvant courses (reduced 
from 3 years to 1 year).   
Despite the problems with sexual dysfunction, urinary difficulties and hormonal issues in some 
groups, this cohort of men living with and beyond the diagnosis of PCa report similar SAH to 
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men in the general population29,30 (Table 3).  Differences in SAH amongst the overall LAPCD 
and general population samples are small, less than 3 points, with minimally important 
differences in EQ-5D SAH ratings having previously been estimated at 7 points26,27.  This 
apparent “resilience” of men with PCa may be accounted for by the “Gap Hypothesis” of quality 
of life, with the diagnosis of a life-threatening illness and subsequent experience of undergoing 
treatment leading to re-calibration of expectations and values31. 
Overall the SAH of men with stage III disease is not markedly different from those with 
localised disease or UK general population surveys.  Whilst scores from those with stage IV 
disease are 6 points lower than those with localised disease, this may not equate to a clinically 
meaningful difference.  A quarter of men with stage IV PCa report no problems in any EQ-5D 
domain.  Not all men with Stage IV PCa experience similar clinical trajectories, with some 
living for prolonged periods and others living significantly shorter periods from diagnosis.  Sub-
groups of men, such those with oligometastatic disease, may experience few problems whilst 
others experience diminished HRQL.  This study did not capture the detailed clinical 
information needed to investigate subtypes of disease.  The absence of other at-scale studies 
of the outcomes of men living with stage III and IV disease prevent comparison with other 
studies.  Further investigation into the outcomes of men living with metastatic disease is 
required, particularly over a longer time period, as many will only develop symptoms a number 
of years after diagnosis. 
Through whole population sampling, potential recruitment or clinical trial intervention bias has 
been avoided.  In addition, all disease stages and treatments have been included, adding 
important new data on men living with and beyond diagnoses of advanced disease who have 
been largely omitted from previous quality of life outcome studies.  Utilisation of a standardised 
set of accepted outcome measures enables future international benchmarking.  Data 
collection at this scale, from all centres in NI, Scotland and Wales and 111 of 136 NHS Trusts 
in England, has allowed us to produce datasets for individual Trusts, Cancer Alliances and 
regional health boards.  Internet-based tools will be made available to support service 
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improvement, and in parallel, a public-facing electronic tool will provide an information and 
decision-making resource for men and their families, through identification of expected 
outcomes based on robust unselected data.  
Four NHS Trusts were excluded from the study as they were participating in an overlapping 
programme32.  A further 21 Trusts did not participate.  Several of these declined because they 
were already participating in other local PROMs studies and were concerned about 
questionnaire fatigue.  The remaining Trusts did not respond to the multiple invitations to take 
part. 
The response rate of 61% is comparable to a similar survey of colorectal cancer survivors in 
England (63%)13.  Comparison of rates with other PCa trials and cohort studies is difficult due 
to different identification and recruitment methods.  Our response rate is reported without 
exclusion or screening of eligible individuals.  Non-respondents were more likely to be older, 
Black, Asian or minority ethnic and live in more socio-economically deprived areas.  These 
are groups who may be expected to potentially experience poorer HRQL.  Variation in 
response rate by stage was identified, with those with stage III disease having the highest 
response rates and those with stage IV disease at diagnosis the lowest.  We do not know if 
patients with worse health status were less likely to respond.  Data completeness was high for 
the majority of questions. Records with missing data were excluded from analysis, which 
assumes that those who did not respond to the question have similar outcomes to those who 
did.  This assumption cannot be validated using the available data.  Men were less likely to 
avoid questions on sexual function than they were for some of the other domains, which is 
perhaps counter-intuitive but could indicate a real concern in this otherwise healthy-feeling 
group. 
Staging information was taken from national cancer registration data at diagnosis and was 
available for 86% of respondents.  The cancer registry uses a variety of data sources, including 
pathology reports and treatment databases, to capture stage information.  Some groups of 
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men are less likely to appear in a treatment or pathology dataset near the time of diagnosis 
(for instance, those on watchful waiting are less likely to have a biopsy).  At the time when 
men in this study were diagnosed, there was less access to multi-disciplinary team systems 
to capture staging information, though this has now improved.  Cancer registries routinely 
derive an area-based measure of socio-economic deprivation using patient postcode and 
completeness of this is high (2% missing in our study).  It was decided to use this measure 
rather than add additional items to an already long questionnaire.  Treatment information was 
self-reported, due to limited data in cancer registries on types of monitoring and difficulties in 
capturing hormone therapies administered through primary care prescriptions (Public Health 
England, Personal Communication).  However, some respondents had difficulty reporting the 
treatments they received (e.g. distinguishing between types of radiotherapy) and these groups 
had to be excluded from some analyses. 
Most men living 18-42 months after diagnosis of PCa can expect to experience as good HRQL 
as men in the general population.  Those diagnosed with locally advanced and metastatic 
disease do not report markedly different HRQL outcomes to those diagnosed with localised 
disease, although significant problems with hormonal function and fatigue are reported as a 
result of ADT.  However, it should be recognised that this study covers a limited window of 
time and HRQL in those with metastatic disease may deteriorate over a longer time period.  
Sexual dysfunction is common across all disease stages, with notably poor provision of sexual 
support.  Our results suggest that there are subgroups of men who would benefit from service 
improvements around sexual rehabilitation and measures to reduce the impact of ADT.  This 
study shows that outcomes for men with PCa are more strongly linked with the treatments 
received than disease stage itself, although clearly the two are intertwined.  These results 
allow clinicians to present very positive goals for quality of survival 18-42 months after 
diagnosis, including for a substantial proportion of men with metastatic disease.  
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Table 1: Characteristics of the study sample split by stage at diagnosis 
    All men Stage I/II Stage III Stage IV Stage unknown 
    n % n % n % n % n % 
Total   35,823 100.0 19,599 54.7 7,209 20.1 3,925 11.0 5,090 14.2 
Treatment 
Active surveillance 2,928 8.2 2,320 11.8 0 0.0 0 0.0 457 9.0 
Watchful waiting 2,292 6.4 1,666 8.5 182 2.5 164 4.2 993 19.5 
Brachytherapy alone 1,208 3.4 940 4.8 62 0.9 13 0.3 294 5.8 
Surgery alone 7,054 19.7 4,606 23.5 1,323 18.4 132 3.4 193 3.8 
Surgery + EBRT/ADT 2,349 6.6 853 4.4 801 11.1 339 8.6 548 10.8 
EBRT alone 2,536 7.1 1,533 7.8 573 7.9 136 3.5 431 8.5 
EBRT + ADT 7,488 20.9 3,688 18.8 2,359 32.7 658 16.8 783 15.4 
ADT alone 3,116 8.7 965 4.9 487 6.8 1,116 28.4 356 7.0 
Systemic + ADT 630 1.8 71 0.4 37 0.5 450 11.5 72 1.4 
Systemic + EBRT (+/- ADT) 513 1.4 84 0.4 128 1.8 237 6.0 64 1.3 
Other treatment groups 5,709 15.9 2873 14.7 1257 17.4 680 17.3 899 17.7 
Age at survey 
<55 years 661 1.8 447 2.3 92 1.3 45 1.1 77 1.5 
55-64 years 5,594 15.6 3,366 17.2 1,026 14.2 473 12.1 729 14.3 
65-74 years 16,638 46.4 9,420 48.1 3,406 47.2 1,712 43.6 2,100 41.3 
75-84 years 11,082 30.9 5,670 28.9 2,391 33.2 1,326 33.8 1,695 33.3 
85+ years 1,842 5.1 696 3.6 294 4.1 369 9.4 483 9.5 
Unknown 6 0.02 0 0.0 0 0.0 0 0.0 6 0.1 
Socio-economic 
deprivation 
quintile 
1 - least deprived 9,408 26.3 5,128 26.2 1,802 25.0 962 24.5 1,516 29.8 
2 9,289 25.9 5,186 26.5 1,889 26.2 1,000 25.5 1,241 24.4 
3 7,381 20.6 4,082 20.8 1,504 20.9 869 22.1 926 18.2 
4 5,266 14.7 2,846 14.5 1,084 15.0 596 15.2 740 14.5 
5 - most deprived 3,620 10.1 1,955 10.0 786 10.9 421 10.7 458 9.0 
Unknown 859 2.4 402 2.1 144 2.0 77 2.0 236 4.6 
No. of other 
long-term 
conditions 
0 10,405 29.0 5,740 29.3 2,087 28.9 1,131 28.8 1,447 28.4 
1 12,527 35.0 6,910 35.3 2,594 36.0 1,316 33.5 1,707 33.5 
2 7,154 20.0 3,827 19.5 1,432 19.9 807 20.6 1,088 21.4 
3 3,174 8.9 1,708 8.7 605 8.4 391 10.0 470 9.2 
≥4 2,563 7.2 1,414 7.2 491 6.8 280 7.1 378 7.4 
EBRT: External beam radiotherapy; ADT: Androgen deprivation therapy; Systemic therapy includes chemotherapy/Abiraterone/Enzalutamide.  
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Table 2: Functional and HRQL outcomes in men diagnosed with prostate cancer 18-42 months previously 
  EPIC-26 domain  EQ-5D dimension Overall HRQL 
 Adjusted mean score* (95% CI) Adjusted % reporting any level of problem* (95% CI) Adjusted result* (95% CI) 
 Urinary 
incontinence 
Urinary 
irritation 
Bowel 
function 
Hormonal 
function 
Sexual 
function Mobility  Self-care 
Usual 
activities 
Pain/ 
discomfort 
Anxiety/ 
depression 
% reporting 
≥1 problem  
Mean SAH 
rating 
  n=31,827 n=29,274 n=30,861 n=31,746 n=32,525 n=35,411 n=35,470 n=35,416 n=35,349 n=35,310 n=34,769 n=35,003 
All men 82.6 85.9 88.9 79.9 24.0 33.8 11.5 36.5 41.7 33.0 63.2 76.3 
 (82.4-82.9) (85.7-86.1) (88.8-89.1) (79.7-80.1) (23.6-24.2) (33.2-34.3) (11.1-11.9) (35.9-37.0) (41.1-42.2) (32.5-33.5) (62.6-63.7) (76.1-76.5) 
      
       
Stage             
I/II 82.9 86.0 89.6 83.6 28.5 29.7 9.8 32.0 38.9 31.0 59.8 77.4 
 (82.6-83.3) (85.8-86.3) (89.4-89.8) (83.3-83.8) (28.1-28.9) (29.0-30.3) (9.4-10.2) (31.3-32.7) (38.1-39.6) (30.3-31.7) (59.1-60.1) (77.2-77.7) 
III 81.2 86.2 87.4 75.3 16.4 34.8 11.6 38.5 42.3 33.9 64.7 76.3 
 (80.7-81.8) (85.8-86.5) (87.0-87.8) (74.8-75.9) (15.9-16.9) (33.6-36.0) (10.8-12.2) (37.3-39.6) (41.1-43.5) (32.8-35.0) (63.6-65.9) (75.9-76.7) 
IV 83.2 84.7 88.1 68.0 11.9 49.8 18.9 53.3 54.6 43.0 76.5 71.7 
 (82.5-83.9) (84.1-85.2) (87.5-88.7) (67.3-68.7) (11.4-12.4) (48.0-51.6) (17.6-20.2) (51.6-55.0) (53.0-56.3) (41.4-44.6) (75.2-77.9) (71.1-72.3) 
 
     
       
Treatment             
AS 87.6 83.0 93.1 90.0 44.6 24.3 7.4 23.9 34.5 30.8 57.3 78.7 
 (87.0-88.3) (82.3-83.6) (92.6-93.6) (89.5-90.5) (43.6-45.7) (22.6-26.0) (6.4-8.3) (22.2-25.5) (32.6-36.3) (29.0-32.5) (55.4-59.2) (78.2-79.3) 
WW 87.1 85.2 93.1 88.0 41.3 31.6 10.4 31.6 36.7 30.9 59.0 77.2 
 (86.3-87.9) (84.6-85.9) (92.6-93.7) (87.4-88.5) (40.0-42.6) (29.6-33.5) (9.3-11.6) (29.7-33.4) (34.8-38.7) (29.0-32.8) (56.9-61.0) (76.5-77.8) 
Brachy alone 89.2 84.1 88.8 89.3 37.6 20.7 5.9 22.9 36.4 25.2 52.6 79.6 
 (88.3-90.1) (83.1-85.0) (87.9-89.7) (88.4-90.1) (36.2-39.0) (18.1-23.2) (4.5-7.3) (20.3-25.5) (33.5-39.3) (22.7-27.7) (49.6-55.6) (78.9-80.4) 
Surg alone 73.5 90.0 93.4 89.6 22.1 23.9 7.6 29.1 33.5 27.3 54.6 79.5 
 (72.8-74.1) (89.7-90.4) (93.1-93.7) (89.2-89.9) (21.5-22.6) (22.8-25.0) (7.0-8.2) (27.9-30.2) (32.3-34.7) (26.2-28.4) (53.3-55.8) (79.2-79.9) 
Surg + EBRT/ADT 73.1 86.1 86.2 76.9 14.9 34.0 11.6 40.0 42.9 35.5 66.1 76.0 
 (71.9-74.2) (85.3-86.8) (85.5-87.0) (76.0-77.8) (14.1-15.7) (32.0-36.0) (10.3-12.8) (37.9-42.1) (40.1-45.0) (33.5-37.4) (64.1-68.1) (75.4-76.7) 
EBRT alone 86.7 86.1 86.2 80.7 25.6 32.8 10.2 33.4 41.2 28.4 59.7 77.6 
 (85.9-87.5) (85.4-86.8) (85.4-87.0) (79.9-81.5) (24.5-26.7) (30.9-34.7) (9.1-11.3) (31.5-35.3) (39.3-43.2) (26.6-30.2) (57.6-61.7) (76.9-78.2) 
EBRT + ADT 86.8 85.5 84.4 72.2 19.1 34.4 10.7 38.0 44.6 34.3 64.8 76.2 
 (86.4-87.3) (85.1-85.8) (84.0-84.9) (71.7-72.7) (18.5-19.6) (33.3-35.6) (10.0-11.4) (36.8-39.2) (43.4-45.7) (33.2-35.4) (63.7-66.0) (75.8-76.5) 
ADT alone 86.4 84.6 90.9 69.3 15.3 43.0 15.9 47.6 46.5 41.0 74.3 72.0 
 (85.7-87.2) (83.9-85.2) (90.3-91.5) (68.5-70.1) (14.6-16.1) (41.0-45.0) (14.6-17.2) (45.6-49.6) (44.5-48.4) (39.1-42.9) (72.5-76.0) (71.3-72.7) 
Syst + ADT 86.2 84.6 90.7 66.9 11.5 55.1 19.5 59.3 57.2 46.4 81.8 70.4 
 (84.5-87.9) (83.3-86.0) (89.6-91.9) (65.2-68.5) (10.4-12.7) (50.7-59.5) (16.2-22.8) (55.1-63.5) (53.1-61.2) (42.4-50.5) (78.7-84.8) (68.9-71.9) 
Syst + EBRT 85.1 83.4 83.8 66.2 12.4 59.5 25.5 62.2 61.7 45.6 82.4 68.3 
  (83.3-86.9) (81.7-85.0) (82.1-85.5) (64.3-68.1) (11.1-13.8) (54.8-64.3) (21.2-29.7) (57.7-66.8) (57.3-66.1) (41.1-50.1) (79.0-85.7) (66.5-70.0) 
*Adjusted for age at survey, socio-economic deprivation and number of other long-term conditions 
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For EPIC-26 scores and SAH ratings, 100=best possible function/health 
AS: Active surveillance; WW: Watchful waiting; Brachy: Brachytherapy; Surg: Surgery; EBRT: External beam radiotherapy; ADT: Androgen deprivation therapy; Syst: Systemic therapy 
(Chemotherapy/Abiraterone/Enzalutamide); SAH: Self-assessed health.  
Due to the large number of men included in the study, statistical significance can be achieved with only small differences in outcomes, and these may not be clinically relevant.  Results should 
be considered alongside previously estimated minimally important differences.  For EPIC-26: Urinary incontinence (6-9 points); Urinary irritation/obstruction (5-7 points); Bowel function (4-6 
points); Vitality/hormone function (4-6 points); Sexual function (10-12 points).  For EQ-5D Self-assessed health (7 points).  
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Table 3: Comparison of self-assessed health ratings in the LAPCD cohort and general 
population surveys (men aged 60 and over) 
  n Mean SAH 
LAPCD   
Stage I/II 18,055 77.8 
Stage III 6,792 76.6 
Stage IV 3,759 71.7 
Overall 33,370 76.5 
   
General population   
Northern Ireland, 20161 2,597 77.2 
Health Survey for England, 20122 1,016 74.2 
SAH: Self-assessed health 
1Northern Ireland General population survey (Donnelly et al. Urinary, bowel and sexual health in older men from 
Northern Ireland. BJU Int 2018. doi: 10.1111/bju.14182). 
2Health Survey for England 2012 (NHS Digital. Available from https://digital.nhs.uk/data-and-
information/publications/statistical/health-survey-for-england/health-survey-for-england-2012). 
